Bionoid Pharma, Inc. Moves to Expand E-Commerce Presence With Binding Agreement to Acquire Platform From Vitawin Supplements Ltd.

December 12, 2024 7:30 AM

Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the signing of a Binding Letter of Intent (LOI) with Vitawin Supplements Ltd. to acquire its premier e-commerce platform, PrimeEnduro.com. This acquisition represents a significant milestone in Bionoid's strategic plan to expand its presence in the health and wellness sector through a scalable and AI-enhanced e-commerce ecosystem.The LOI outlines that Bionoid will retain all...

Read more

BioInvent Announces First Patient Enrolled in Phase 1b/2a Study of BI-1607 in Combination with Ipilimumab and KEYTRUDA (Pembrolizumab) in Patients with Unresectable or Metastatic Melanoma

December 12, 2024 2:20 AM

Study to evaluate safety and anti-tumoral activity of anti-FcgRIIB antibody BI-1607 with anti-CTLA-4: ipilimumab, in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA)( anti-PD-1 therapy, KEYTRUDA® (pembrolizumab); initial data expected in H2 2025Data from Phase 1 study in combination with trastuzumab previously demonstrated BI-1607 is safe, well tolerated and achieves full receptor occupancy during the treatment interval at several...

Read more

Agreement Signed with US Insurance Giant and Expanded Market

December 12, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / December 12, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)SEK tQ2 24/25Q2 23/24May-Oct 24/25May-Oct 23/24Full year 23/24Net sales2,3122,5634,0274,3167,290Operating profit (loss)-19,753-25,316-43,316-57,508-126,845Profit (loss) for the period-21,152-25,684-44,041-57,949-124,823Earnings per share, after dilution-0.23-0.56-0.50-1.27-2.14Average number of shares during the...

Read more

CARDIO inCode Publication in International Journal of Cardiology Cardiovascular Risk and Prevention

December 11, 2024 8:00 AM

GENinCode U.S., the genetics company focused on the prevention of cardiovascular disease, announces the publication in the International Journal of Cardiology Cardiovascular Risk and Prevention of a clinical research study on the ‘Interplay between Lifestyle Factors and Polygenic Risk for Incident Coronary Heart Disease in a Large Multiethnic Cohort' 1.The publication investigated a subset of over 60,000 adult individuals with no history of...

Read more

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

December 6, 2024 4:15 PM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement.The agreement includes the issuance of 961,446 shares of common stock (or common stock equivalents) and warrants to purchase up...

Read more

ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium

December 6, 2024 12:30 PM

TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium.PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the...

Read more

Biovica CLIA Lab Achieves New York State Permit that Opens the Entire US Market

December 6, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / December 06, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B) (FRA:9II) Biovica, active in blood-based cancer monitoring, today announces that the company has obtained an out-of-state permit allowing Biovica to offer testing to patients in New York State. Together with previous permits, Biovica is now allowed to offer DiviTum® TKa in all 50 states in the US and Puerto Rico.The permit was granted by the New...

Read more

Axonia Medical Announces Exclusive Partnerships with Leading Biotechnology and Microbiology Equipment Manufacturers

December 5, 2024 12:30 PM

SINGAPORE, SINGAPORE / ACCESSWIRE / December 5, 2024 / Axonia Medical is a leading provider of lab equipment. The company is excited to announce its exclusive partnerships. These partnerships are with well-known manufacturers in the biotechnology and microbiology fields. Axonia Medical collaborates with major companies. These include Abbott, Beckman Coulter, Sysmex, Roche, Bio-Rad, Mindray, Siemens, Horiba, and Perkin Elmer. This helps labs...

Read more

TeselaGen Launches Its Next-Gen Electronic Lab Notebook and Enhanced Interface to Accelerate Biotech Research

December 5, 2024 10:00 AM

TeselaGen Biotechnology, a leader in advanced software solutions for the biotechnology industry, has announced the release of its new Electronic Lab Notebook (ELN) alongside a unified user interface designed to improve user experience. These advancements are set to streamline laboratory workflows, improve data management, and foster collaboration among scientists in the biotech sector.TeselaGen's Electronic Lab Notebook (ELN) The TeselaGen ELN...

Read more

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

December 5, 2024 8:45 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has entered into a Clinical Trial Services Agreement (the "Agreement") with the Israel-based biotechnology company PeriNess Ltd. ("PeriNess") to advance the Company's development program for its systemic DNase I candidate in combination...

Read more

Senior Pharma and Biotech Leaders to Gather the Weekend Immediately Prior to JP Morgan Healthcare Conference for 2 Day Networking Forum, San Francisco CEO, Hosted by Longwood Healthcare Leaders

December 5, 2024 7:00 AM

BOSTON, MA / ACCESSWIRE / December 4, 2024 / Longwood Healthcare Leaders will convene top biopharmaceutical leaders for two days of discussion, January 11-12, 2025, the weekend immediately prior to the 43rd Annual JP Morgan Health Care Conference. San Francisco CEO is held at the Four Seasons Hotel San Francisco, 757 Market Street, in downtown San Francisco, and features approximately 150 speakers across government, pharma, biotech, academia,...

Read more

Indica Labs Joins the AWS Partner Network

December 4, 2024 8:00 AM

Indica Labs, the global leader in AI-powered digital pathology software and services, announced today that they have joined the Amazon Web Services (AWS) Partner Network (APN). The APN is a global community of AWS Partners that leverage programs, expertise, and resources to build, market, and co-sell customer offerings. With the successful completion of the foundational technical review of HALO®, HALO AI, HALO Link, and HALO AP®, these platforms...

Read more

Alligator Bioscience Publishes Financial Calendar for 2025

December 4, 2024 3:00 AM

LUND, SE / ACCESSWIRE / December 04, 2024 / Alligator Bioscience (STO:ATORX) Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2025:Extraordinary General Meeting13 January 2025Deadline for Alligator Bioscience's shareholders to submit resolutions to be considered by the Annual General Meeting31 January 2025Year-end report 202422 January 2025Annual report 2024March 2025Interim report Q1...

Read more

Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial

December 4, 2024 2:50 AM

LUND, SE / ACCESSWIRE / December 04, 2024 / Alligator Bioscience (STO:ATORX)Lund, Sweden, November 27, 2024 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Company was notified that the first patient has been dosed in a Phase 3 clinical trial with Shanghai Henlius Biotech, Inc. Alligator out-licensed HLX22/AC101 to AbClon, Inc. in October 2016. Abclon, Inc. subsequently sub-licensed AC101 for clinical development by...

Read more

BioInvent Appoints Ashley Robinson as SVP Strategy & Finance to Lead US Expansion

December 3, 2024 2:30 AM

LUND, SWEDEN and BOSTON, MA / ACCESSWIRE / December 3, 2024 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces the appointment of Ashley Robinson as SVP Strategy & Finance, effective as of today. In this role, Mr. Robinson will spearhead efforts to strengthen BioInvent's...

Read more

Exercise price determined for the exercise of warrants series TO 9 in Alligator Bioscience AB

December 2, 2024 11:35 AM

LUND, SE / ACCESSWIRE / December 2, 2024 / Alligator Bioscience (STO:ATORX) Alligator Bioscience AB ("Alligator" or the "Company") hereby announces that the exercise price for warrants series TO 9 (the "warrants") has been determined to SEK 0.55. The exercise period for the warrants commences on 4 December 2024 and runs up to and including 18 December 2024. The last day for trading in the warrants is 13 December 2024.Alligator carried out a...

Read more

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

December 2, 2024 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today an expansion of its clinical research program for IGC-AD1, an investigational treatment for Alzheimer's disease. Building on Phase 2 interim results demonstrating reductions in agitation and cognitive improvement, the Company is initiating new trials to evaluate IGC-AD1's potential as a disease-modifying therapy.The expanded research will explore how IGC-AD1's...

Read more

Alligator Sharpens Focus on Mitazalimab and Announces Cost Reduction Program to Maximize Long-Term Value Creation

December 2, 2024 3:00 AM

Sharpening focus on preparing mitazalimab for Phase 3 and continuing partnering discussionsPlanned reduction of workforce, mainly within Discovery and Non-Clinical unitExpected annual cash savings of at least SEK 65 millionWill continue to conduct limited research activities, primarily related to mitazalimabLUND, SE / ACCESSWIRE / December 02, 2024 / Alligator Bioscience AB ("Alligator" or the "Company") announced today that it is sharpening its...

Read more

Notice of Extraordinary General Meeting in Alligator Bioscience AB

December 2, 2024 3:00 AM

LUND, SE / ACCESSWIRE / December 02, 2024 / Alligator Bioscience (STO:ATORX) The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the extraordinary general meeting to be held on Monday 13 January 2025 at 11.30 CET, at Medicon Village, conference room Bengt,...

Read more

Alligator Bioscience Carries out a Rights Issue of Units of Approximately SEK 280 Million and Raises Bridge Loans

December 2, 2024 3:00 AM

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.LUND, SE / ACCESSWIRE / December 02, 2024 / Alligator Bioscience (STO:ATORX) The Board of...

Read more